Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rayne H Rouce

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
Cancer Discovery|June 5, 2016
Forecasting Cytokine Storms with New Predictive BiomarkersRayne H Rouce, Helen E Heslop
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 4, 2025
How to democratize cell and gene therapy: A global approachRayne H Rouce, Bambi J Grilley
Best Practice & Research. Clinical Haematology|August 23, 2023
Targeted cellular therapy for treatment of relapsed or refractory leukemiaLauren D Scherer, Rayne H Rouce
Blood|June 24, 2017
Equal opportunity CAR T cellsRayne H Rouce, Helen E Heslop
Science (New York, N.Y.)|August 1, 2024
Cell and gene therapy accessibilityRayne H Rouce, Matthew H Porteus
Hematology. American Society of Hematology. Education Program|December 4, 2020
Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphomaEmily M Hsieh, Rayne H Rouce
Hematology. American Society of Hematology. Education Program|December 7, 2024
EBV and post-transplant lymphoproliferative disorder: a complex relationshipNader Kim El-Mallawany, Rayne H Rouce
Boletin Medico Del Hospital Infantil De Mexico|February 9, 2018
Recent advances in the risk factors, diagnosis and management of Epstein-Barr virus post-transplant lymphoproliferative diseasePaibel Aguayo-Hiraldo, Reuben Arasaratnam, Rayne H Rouce
The Journal of Clinical Investigation|May 5, 2020
Replacing CAR-T cell resistance with persistence by changing a single residueEmily M Hsieh, Lauren D Scherer, Rayne H Rouce
Current Opinion in Hematology|August 28, 2014
Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplantRayne H Rouce, Chrystal U Louis, Helen E Heslop
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Cancer Discovery|June 5, 2016
Forecasting Cytokine Storms with New Predictive BiomarkersRayne H Rouce, Helen E Heslop
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 4, 2025
How to democratize cell and gene therapy: A global approachRayne H Rouce, Bambi J Grilley
Best Practice & Research. Clinical Haematology|August 23, 2023
Targeted cellular therapy for treatment of relapsed or refractory leukemiaLauren D Scherer, Rayne H Rouce
Blood|June 24, 2017
Equal opportunity CAR T cellsRayne H Rouce, Helen E Heslop
Science (New York, N.Y.)|August 1, 2024
Cell and gene therapy accessibilityRayne H Rouce, Matthew H Porteus
Hematology. American Society of Hematology. Education Program|December 4, 2020
Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphomaEmily M Hsieh, Rayne H Rouce
Hematology. American Society of Hematology. Education Program|December 7, 2024
EBV and post-transplant lymphoproliferative disorder: a complex relationshipNader Kim El-Mallawany, Rayne H Rouce
Boletin Medico Del Hospital Infantil De Mexico|February 9, 2018
Recent advances in the risk factors, diagnosis and management of Epstein-Barr virus post-transplant lymphoproliferative diseasePaibel Aguayo-Hiraldo, Reuben Arasaratnam, Rayne H Rouce
The Journal of Clinical Investigation|May 5, 2020
Replacing CAR-T cell resistance with persistence by changing a single residueEmily M Hsieh, Lauren D Scherer, Rayne H Rouce
Current Opinion in Hematology|August 28, 2014
Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplantRayne H Rouce, Chrystal U Louis, Helen E Heslop
Pageof 6